(NASDAQ: HURA) Tuhura Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.38%.
Tuhura Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast HURA's revenue for 2028 to be $2,326,417,891, with the lowest HURA revenue forecast at $2,326,417,891, and the highest HURA revenue forecast at $2,326,417,891. On average, 1 Wall Street analysts forecast HURA's revenue for 2029 to be $4,745,438,221, with the lowest HURA revenue forecast at $4,745,438,221, and the highest HURA revenue forecast at $4,745,438,221.
In 2030, HURA is forecast to generate $7,260,555,423 in revenue, with the lowest revenue forecast at $7,260,555,423 and the highest revenue forecast at $7,260,555,423.